METHOD FOR PREDICTING THE DEVELOPMENT OF LIFE-THREATENING VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH IN PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE WITH A REDUCED EJECTION FRACTION WITHIN 12 MONTHS AFTER IMPLANTATION OF A CARDIOVERTER DEFIBRILLATOR Russian patent published in 2021 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used in cardiology, angiology, cardiac surgery, therapy, rehabilitation. Before the implantation of a cardioverter defibrillator, galectin-3 in the blood serum is determined in the patient by an enzyme immunoassay. With a galectin-3 level of 16.6 ng/ml or more, patients with coronary heart disease and heart failure with a reduced left ventricular ejection fraction are predicted to have a high risk of developing life-threatening ventricular arrhythmias and sudden cardiac death during the next 12 months of follow-up after implantation of a cardioverter defibrillator. The method makes it possible to predict a life-threatening risk by determining a fibrosis marker in the blood serum, galein-3, which makes it possible to identify a priority group of patients with an increased risk of cardiovascular complications for dispensary observation with the organization of effective targeted measures aimed at preventing ventricular arrhythmias and sudden cardiac death.

EFFECT: method makes it possible to predict a high risk of life-threatening ventricular arrhythmias and sudden cardiac death caused by excessive fibroblast proliferation, collagen deposition and cardiac remodeling during 12 months of follow-up after implantation of a cardioverter defibrillator.

1 cl, 1 dwg, 1 tbl, 2 ex